论文信息 - Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC). - 字舞流文

Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC).

C. Garrett | T. Reid | J. Hecht | U. Brandt | J. Beck | S. Sharma | S. Hoosen | S. Davidson | M. Mackenzie | S. Sharma